According to filings with the U.S. Securities and Exchange Commission, Altesa BioSciences is raising up to $74,999,986.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Altesa BioSciences
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations — namely viral respiratory infections — starting with rhinovirus, the most common respiratory virus on the planet. Our goal is to disrupt the COPD treatment paradigm by targeting the upstream cause of acute respiratory exacerbations — not accept the status quo of managing the long term downstream consequences like chronic inflammation, hospitalizations and even death.

To learn more about Altesa BioSciences, visit https://www.altesabio.com/
Altesa BioSciences Linkedin Page: https://www.linkedin.com/company/altesa-biosciences/

Contact:
John Clerici, President and Chief Operating Officer
703-795-4274
https://www.linkedin.com/in/john-clerici-b013bb29/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.